Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated ...

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value as off-the-shelf options for patients post chimeric antigen receptor ...

If patients with breast cancer hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.